Retrospective Assessment of the Antigenic Similarity of Egg-Propagated and Cell Culture-Propagated Reference Influenza Viruses as Compared with Circulating Viruses across Influenza Seasons 2002-2003 to 2017-2018.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
28 07 2020
Historique:
received: 11 06 2020
revised: 24 07 2020
accepted: 25 07 2020
entrez: 1 8 2020
pubmed: 1 8 2020
medline: 25 11 2020
Statut: epublish

Résumé

Suboptimal vaccine effectiveness against seasonal influenza is a significant public health concern, partly explained by antigenic differences between vaccine viruses and viruses circulating in the environment. Haemagglutinin mutations within vaccine viruses acquired during serial passage in eggs have been identified as a source of antigenic variation between vaccine and circulating viruses. This study retrospectively compared the antigenic similarity of circulating influenza isolates with egg- and cell-propagated reference viruses to assess any observable trends over a 16-year period. Using annual and interim reports published by the Worldwide Influenza Centre, London, for the 2002-2003 to 2017-2018 influenza seasons, we assessed the proportions of circulating viruses which showed antigenic similarity to reference viruses by season. Egg-propagated reference viruses were well matched against circulating viruses for A/H1N1 and B/Yamagata. However, A/H3N2 and B/Victoria cell-propagated reference viruses appeared to be more antigenically similar to circulating A/H3N2 and B/Victoria viruses than egg-propagated reference viruses. These data support the possibility that A/H3N2 and B/Victoria viruses are relatively more prone to egg-adaptive mutation. Cell-propagated A/H3N2 and B/Victoria reference viruses were more antigenically similar to circulating A/H3N2 and B/Victoria viruses over a 16-year period than were egg-propagated reference viruses.

Identifiants

pubmed: 32731417
pii: ijerph17155423
doi: 10.3390/ijerph17155423
pmc: PMC7432082
pii:
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Vaccine. 2019 Sep 16;37(39):5807-5811
pubmed: 31445771
Vaccine. 2006 Nov 10;24(44-46):6683-90
pubmed: 17030498
Clin Infect Dis. 2018 Sep 14;67(7):1129-1131
pubmed: 29672670
J Virol. 2005 Jun;79(11):6763-71
pubmed: 15890915
PLoS One. 2020 Feb 26;15(2):e0229279
pubmed: 32101582
Hum Vaccin Immunother. 2018 Mar 4;14(3):724-735
pubmed: 28481673
Elife. 2015 Jan 16;4:e05055
pubmed: 25594904
Clin Infect Dis. 2019 Oct 30;69(10):1817-1823
pubmed: 31102401
Clin Infect Dis. 2018 Oct 15;67(9):1474-1476
pubmed: 29688295
BMC Biol. 2016 Dec 29;14(1):117
pubmed: 28034300
J Infect Dis. 2019 Sep 13;220(8):1255-1264
pubmed: 30561688
N Engl J Med. 2017 Jun 22;376(25):2427-2436
pubmed: 28636855
PLoS One. 2014 Apr 03;9(4):e93632
pubmed: 24699432
Vaccine. 2018 Apr 12;36(16):2166-2175
pubmed: 29548608
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
J Gen Virol. 2017 Jun;98(6):1274-1281
pubmed: 28612701
J Infect Dis. 2017 Jun 15;215(12):1782-1788
pubmed: 28398521
Clin Infect Dis. 2018 Jul 18;67(3):327-333
pubmed: 29471464
MMWR Morb Mortal Wkly Rep. 2017 Jun 30;66(25):668-676
pubmed: 28662019
Clin Infect Dis. 2019 Sep 13;69(7):1198-1204
pubmed: 30561532
J Virol. 2010 Aug;84(16):8287-99
pubmed: 20519409
Vaccine. 2006 May 1;24(18):3881-8
pubmed: 16460844
J Virol. 2015 Nov;89(21):10993-1001
pubmed: 26311890
PLoS One. 2015 Oct 06;10(10):e0139958
pubmed: 26440103
Lancet Respir Med. 2018 Jan;6(1):1
pubmed: 29303744
Clin Vaccine Immunol. 2012 Jun;19(6):897-908
pubmed: 22492743
J Clin Microbiol. 2014 May;52(5):1672-7
pubmed: 24622097
N Engl J Med. 2018 Jan 4;378(1):7-9
pubmed: 29185857
J Infect Dis. 2018 Oct 5;218(10):1571-1581
pubmed: 29931203
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
JAMA. 2004 Sep 15;292(11):1333-40
pubmed: 15367555
PLoS Biol. 2005 Sep;3(9):e300
pubmed: 16026181
Clin Immunol. 2014 Mar;151(1):55-65
pubmed: 24525048
PLoS One. 2014 Mar 25;9(3):e92153
pubmed: 24667168
PLoS Pathog. 2017 Oct 23;13(10):e1006682
pubmed: 29059230
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):634-642
pubmed: 29879098
Euro Surveill. 2017 Oct;22(43):
pubmed: 29090681
J Virol. 2010 Jul;84(13):6769-81
pubmed: 20410266

Auteurs

Sankarasubramanian Rajaram (S)

Seqirus UK Ltd., Maidenhead SL6 8AA, UK.

Pirada Suphaphiphat (P)

Seqirus UK Ltd., Maidenhead SL6 8AA, UK.

Josephine van Boxmeer (J)

Seqirus UK Ltd., Maidenhead SL6 8AA, UK.

Mendel Haag (M)

Seqirus UK Ltd., Maidenhead SL6 8AA, UK.

Brett Leav (B)

Seqirus UK Ltd., Maidenhead SL6 8AA, UK.

Ike Iheanacho (I)

Evidera Ltd., London W6 8BJ, UK.

Kristin Kistler (K)

Evidera Inc., Waltham, MA 02451, USA.

Raúl Ortiz de Lejarazu (R)

School of Medicine, University of Valladolid, 47005 Valladolid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH